<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889574</url>
  </required_header>
  <id_info>
    <org_study_id>071.PHA.2018.D</org_study_id>
    <nct_id>NCT03889574</nct_id>
  </id_info>
  <brief_title>Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization</brief_title>
  <official_title>Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim(s)/Objective(s)&#xD;
&#xD;
        -  To evaluate the safety and efficacy of triple antithrombotic therapy in patients taking&#xD;
           DAPT of aspirin and a P2Y12 inhibitor in addition to either a NOAC or warfarin for the&#xD;
           prevention of thromboembolic or acute coronary syndrome (ACS) events in patients with&#xD;
           non-valvular atrial fibrillation (AF), history of coronary artery disease (CAD)/stent&#xD;
           placement or recurrent ACS event.&#xD;
&#xD;
        -  To determine the Methodist Health System (MHS) prescribing practices and patterns in&#xD;
           cardiac patients with a history of AF who are admitted for CAD or an ACS event requiring&#xD;
           PCI.&#xD;
&#xD;
      Hypothesis Primary Hypothesis Cardiac patients with a history of AF and an indication for&#xD;
      long-term NOAC who are also prescribed DAPT following an ASC event or revascularization with&#xD;
      stenting will demonstrate a significant difference in cardiovascular outcomes and major&#xD;
      bleeding events when compared with warfarin-based triple therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN&#xD;
&#xD;
        -  Multi-center, retrospective cohort chart review study design&#xD;
&#xD;
        -  Data will be collected on all triple therapy recipients who were discharged from a&#xD;
           Methodist Health System (MHS) facility with prescriptions for a combination of aspirin,&#xD;
           P2Y12 Inhibitor and an OAC of either a NOAC or warfarin between April 1, 2017 - April 1,&#xD;
           2018&#xD;
&#xD;
        -  Patient list will be generated in EPIC&#xD;
&#xD;
        -  All data will be obtained from EPIC&#xD;
&#xD;
        -  All data will be collected retrospectively after the patient is discharged from the&#xD;
           hospital&#xD;
&#xD;
        -  Data collection (planned completion date): May 2019&#xD;
&#xD;
      Study Inclusion Criteria:&#xD;
&#xD;
        -  18 years or older&#xD;
&#xD;
        -  AF diagnosis&#xD;
&#xD;
        -  ICD10 for ACS, STEMI or NSTEMI&#xD;
&#xD;
        -  Discharged with triple therapy agents of aspirin, P2Y12 inhibitor (clopidogrel,&#xD;
           prasugrel, or ticagrelor), and OAC (warfarin, edoxaban, dabigatran, rivaroxaban, or&#xD;
           apixaban) status post-stent&#xD;
&#xD;
      Study Exclusion Criteria:&#xD;
&#xD;
        -  Patients less than 18 years of age&#xD;
&#xD;
        -  Prior intracranial bleeding prior to study start date&#xD;
&#xD;
        -  GI hemorrhage within 1 month prior to study start date&#xD;
&#xD;
        -  Major bleeding event with 1 month prior to study start date&#xD;
&#xD;
        -  Hemorrhage disorder&#xD;
&#xD;
        -  Stroke within 1 month prior to study start date&#xD;
&#xD;
        -  Cardiogenic shock during admission at start date&#xD;
&#xD;
        -  Contraindication to use of the study medications&#xD;
&#xD;
        -  Peptic ulcer in the prior 6 months prior to study start date&#xD;
&#xD;
        -  Thrombocytopenia (platelet concentration lower than 50×109/L)&#xD;
&#xD;
        -  Thrombolysis In Myocardial Infarction (TIMI) major bleeding in the prior 12 months of&#xD;
           study start date&#xD;
&#xD;
        -  Pregnancy&#xD;
&#xD;
        -  History of DVT or PE currently on OAC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Actual">June 27, 2019</completion_date>
  <primary_completion_date type="Actual">June 27, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between warfarin based triple therapy versus NOAC-based triple therapy in cardiac patients</measure>
    <time_frame>April 1, 2017 - April 1, 2018</time_frame>
    <description>To compare the incidence of MACE, stroke (ischemic and hemorrhage), MI (STEMI and NSTEMI), stent thrombosis, systemic embolism (VTE), death (all-cause, cardiac and non-cardiac) and CAD-associated hospitalizations/ED visits) in patients who received warfarin-based triple therapy versus NOAC-based triple therapy.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>combination of aspirin, P2Y12 Inhibitor with a NOAC</arm_group_label>
    <description>As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination of aspirin, P2Y12 Inhibitor with warfarin</arm_group_label>
    <description>As this is a retrospective study with limited patients available for the cohort, all patients meeting inclusion criteria from April 1, 2017 - April 1, 2018 will be included to obtain the largest sample size possible</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiac patients with a history of AF and an indication for long-term NOAC who are also&#xD;
        prescribed DAPT following an ASC event or revascularization with stenting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • 18 years or older&#xD;
&#xD;
               -  AF diagnosis&#xD;
&#xD;
               -  ICD10 for ACS, STEMI or NSTEMI&#xD;
&#xD;
               -  Discharged with triple therapy agents of aspirin, P2Y12 inhibitor (clopidogrel,&#xD;
                  prasugrel, or ticagrelor), and OAC (warfarin, edoxaban, dabigatran, rivaroxaban,&#xD;
                  or apixaban) status post-stent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients less than 18 years of age&#xD;
&#xD;
               -  Prior intracranial bleeding prior to study start date&#xD;
&#xD;
               -  GI hemorrhage within 1 month prior to study start date&#xD;
&#xD;
               -  Major bleeding event with 1 month prior to study start date&#xD;
&#xD;
               -  Hemorrhage disorder&#xD;
&#xD;
               -  Stroke within 1 month prior to study start date&#xD;
&#xD;
               -  Cardiogenic shock during admission at start date&#xD;
&#xD;
               -  Contraindication to use of the study medications&#xD;
&#xD;
               -  Peptic ulcer in the prior 6 months prior to study start date&#xD;
&#xD;
               -  Thrombocytopenia (platelet concentration lower than 50×109/L)&#xD;
&#xD;
               -  Thrombolysis In Myocardial Infarction (TIMI) major bleeding in the prior 12&#xD;
                  months of study start date&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  History of DVT or PE currently on OAC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1433-41. doi: 10.1001/archinternmed.2010.271.</citation>
    <PMID>20837828</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICD10 for ACS, STEMI or NSTEMI, Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

